Tango Therapeutics, Inc.
TNGX
$17.95
$0.653.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 363.61% | -83.99% | -16.67% | -24.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 363.61% | -83.99% | -16.67% | -24.19% |
| Cost of Revenue | -5.41% | -7.36% | -15.13% | -4.26% | 8.29% |
| Gross Profit | -7.65% | 206.19% | -57.76% | 1.72% | -15.10% |
| SG&A Expenses | -11.97% | -20.48% | 5.27% | 7.68% | 21.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.02% | -10.67% | -10.68% | -1.65% | 11.33% |
| Operating Income | -2.33% | 142.80% | -38.63% | -0.65% | -16.84% |
| Income Before Tax | -3.14% | 154.53% | -52.31% | -5.20% | -22.48% |
| Income Tax Expenses | -212.24% | -118.52% | -46.15% | -15.00% | 4.26% |
| Earnings from Continuing Operations | -2.86% | 154.46% | -52.06% | -5.17% | -22.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.86% | 154.46% | -52.06% | -5.17% | -22.45% |
| EBIT | -2.33% | 142.80% | -38.63% | -0.65% | -16.84% |
| EBITDA | -2.72% | 145.35% | -39.50% | -0.67% | -17.14% |
| EPS Basic | 15.03% | 153.24% | -49.00% | -3.14% | -9.54% |
| Normalized Basic EPS | 10.02% | 153.31% | -49.22% | -1.15% | -2.04% |
| EPS Diluted | 15.03% | 148.15% | -49.00% | -3.14% | -9.54% |
| Normalized Diluted EPS | 10.02% | 150.21% | -49.22% | -1.15% | -2.04% |
| Average Basic Shares Outstanding | 21.08% | 2.27% | 2.06% | 1.97% | 11.79% |
| Average Diluted Shares Outstanding | 21.08% | 8.55% | 2.06% | 1.97% | 11.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |